Vaccine (Live attenuated vaccine) · Immune activation, directed at rabies virus glycoprotein · developed by Kamada
Rabies Virus Strain Flury LEP Antigen is an active rabies vaccine given as 1.0 ml doses on days 0, 3, 7, 14 and 28, with the first dose timed around rabies immune globulin injection. It is studied for prevention of rabies.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02040090 | Phase 2/3 | Rabies | Completed | KMDA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Rabies
Updated Oct 18, 2026. Something wrong or missing? Report it on the KMDA page.
See KMDA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
KMDA catalysts and pipeline →